Author(s):
Shashikala Bhagat, Renuka Ekka, Bharti Ahirwar
Email(s):
bhagatshashikala48@gmail.com
DOI:
10.52711/0974-360X.2025.00488 
Address:
Shashikala Bhagat*, Renuka Ekka, Bharti Ahirwar
Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Koni, Bilaspur, Chhattisgarh, India-495009.
*Corresponding Author
Published In:
Volume - 18,
Issue - 7,
Year - 2025
ABSTRACT:
Breast cancer (BC) is the most commonly diagnosed cancer among women excluding nonmelanoma of the skin. It is the second most common cause of death from cancer among women overall. The purpose of this study was to evaluate people's awareness and knowledge regarding breast cancer. Collectively, parent-inherited gene alterations are thought to be responsible for 5–10% of breast cancer cases. An inherited mutation in either the BRCA1 or BRCA2 gene is the most typical reason for hereditary breast cancer. It also has non-genetic factors including environmental factors. Based on both molecular and histological evidence BC could be categorized into three groups; BC expressing hormone receptor (estrogen receptor (ER+) or progesterone receptor (PR+)), BC expressing human epidermal receptor 2 (HER2+) and triple-negative breast cancer (TNBC) (ER-, PR-, HER2-). Based on a recent study and available data out of one lakh individuals, approximately 35 women were expected to have breast cancer in 2015. Physicians have also noted that women under 40 years of age accounted for 30% of all incidences of breast cancer and this percentage is steadily rising. Main challenges emerging from the healthcare demand worldwide regard long-term care of chronic conditions. TNBCs are a heterogeneous and aggressive form of cancer, for which there are no scientifically validated biologically targeted effective treatments. The lack of ERs, PRs, and HER2 makes finding a reliable treatment alternative for TNBC. some herbal remedies as complementary therapies to manage adverse consequences of cancer therapy, improve their overall well-being, and support their immune system.
Cite this article:
Shashikala Bhagat, Renuka Ekka, Bharti Ahirwar. A Comprehensive data to Understanding the Molecular Mechanism Involving Breast Cancer. Research Journal of Pharmacy and Technology. 2025;18(7):3374-4. doi: 10.52711/0974-360X.2025.00488
Cite(Electronic):
Shashikala Bhagat, Renuka Ekka, Bharti Ahirwar. A Comprehensive data to Understanding the Molecular Mechanism Involving Breast Cancer. Research Journal of Pharmacy and Technology. 2025;18(7):3374-4. doi: 10.52711/0974-360X.2025.00488 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-7-68
9. REFERENCES:
1. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL. Breast cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022 Nov; 72(6):524-41.
2. Fortner BV, Stepanski EJ, Wang SC, Kasprowicz S, Durrence HH. Sleep and quality of life in breast cancer patients. Journal of Pain and Symptom Management. 2002 Nov 1;24(5):471-80.
3. Goff SL, Danforth DN. The role of immune cells in breast tissue and immunotherapy for the treatment of breast cancer. Clinical Breast Cancer. 2021 Feb 1;21(1): e63-73.
4. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, Liu B. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes & Diseases. 2018 Jun 1;5(2):77-106.
5. Baksh M, Mahajan B, Dufresne MM, Shoukry MM, Nussbaum S, Abbaszadeh-Kasbi A, Ashary M, Vandenberg J, Gabriel EM. Circulating tumor DNA for breast cancer: Review of active clinical trials. Cancer Treatment and Research Communications. 2022 Jul 12:100609.
6. Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L. Breast cancer: Biology, biomarkers, and treatments. International Immunopharmacology. 2020 Jul 1; 84:106535.
7. Ruiz-Casado A, Alvarez-Bustos A, de Pedro CG, Mendez-Otero M, Romero-Elias M. Cancer-related fatigue in breast cancer survivors: a review. Clinical Breast Cancer. 2021 Feb 1;21(1):10-25.
8. Moshina N, Falk RS, Hofvind S. Long-term quality of life among breast cancer survivors eligible for screening at diagnosis: a systematic review and meta-analysis. Public Health. 2021 Oct 1; 199:65-76.
9. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer: Targets and Therapy. 2019 Apr 10:151-64.
10. Wu HT, Lin J, Liu YE, Chen HF, Hsu KW, Lin SH, Peng KY, Lin KJ, Hsieh CC, Chen DR. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway. Phytomedicine. 2021 Jan 1; 81:153437.
11. Wang X, Yang Y, A Y, Fang G. The mechanism of anticancer action and potential clinical use of kaempferol in the treatment of breast cancer. Biomedicine & Pharmacotherapy. 2019 Sep 1; 117:109086.
12. Farghadani R, Naidu R. The anticancer mechanism of action of selected polyphenols in triple-negative breast cancer (TNBC). Biomedicine & Pharmacotherapy. 2023 Sep 1; 165:115170.
13. Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer: Targets and Therapy. 2022 Jan 11:15-24.
14. Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. International Journal of Women's Health. 2019 Jul 31:431-7.
15. Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: Promising prognostic biomarkers currently in development. Expert Review of Anticancer Therapy. 2021 Feb 1;21(2):135-48.
16. Bodewes FT, van Asselt AA, Dorrius MD, Greuter MJ, de Bock GH. Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis. The Breast. 2022 Sep 26.
17. Triberti S, Savioni L, Sebri V, Pravettoni G. eHealth for improving quality of life in breast cancer patients: a systematic review. Cancer Treatment Reviews. 2019 Mar 1; 74:1-4.
18. Venetis K, Invernizzi M, Sajjadi E, Curigliano G, Fusco N. Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. Cancer Treatment Reviews. 2020 Nov 1; 90:102089.
19. Moragon S, Di Liello R, Bermejo B, Hernando C, Olcina E, Chirivella I, Lluch A, Cejalvo JM, Martínez MT. Fertility and breast cancer: A literature review of counseling, preservation options and outcomes. Critical Reviews in Oncology/Hematology. 2021 Oct 1; 166:103461.
20. Shareef M, Ashraf MA, Sarfraz M. Natural cures for breast cancer treatment. Saudi Pharmaceutical Journal. 2016 May 1;24(3):233-40.
21. Kim W, Lee WB, Lee JW, Min BI, Baek SK, Lee HS, Cho SH. Traditional herbal medicine as adjunctive therapy for breast cancer: A systematic review. Complementary Therapies in Medicine. 2015 Aug 1;23(4):626-32.
22. Richie RC, Swanson JO. Breast cancer: a review of the literature. Journal of Insurance Medicine-New York Then Denver. 2003 Jan 1;35(2):85-101.
23. Salimifard S, Masjedi A, Hojjat-Farsangi M, Ghalamfarsa G, Irandoust M, Azizi G, Mohammadi H, Keramati MR, Jadidi-Niaragh F. Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer. Pathology-Research and Practice. 2020 May 1;216(5):152915.
24. Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LM, Jiang M, Raso MG, Wang S, Bell D. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Modern Pathology. 2021 Apr 1;34(4):710-9.
25. Nguyen AT, Shiao SL, McArthur HL. Advances in combining radiation and immunotherapy in breast cancer. Clinical Breast Cancer. 2021 Apr 1;21(2):143-52.
26. Gupta V, Vasudev M, Doegar A, Sambyal N. Breast cancer detection from histopathology images using modified residual neural networks. Biocybernetics and Biomedical Engineering. 2021 Oct 1; 41(4):1272-87.
27. Carter SM, Rogers W, Win KT, Frazer H, Richards B, Houssami N. The ethical, legal and social implications of using artificial intelligence systems in breast cancer care. The Breast. 2020 Feb 1; 49:25-32.
28. Nascimento C, Ferreira F. Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model. Biochimica et Biophysical Acta (BBA)-Reviews on Cancer. 2021 Aug 1;1876(1):188587.
29. Marino M, Galluzzo P, Ascenzi PJCg. Estrogen signaling multiple pathways to impact gene transcription. 2006;7(8):497-508.
30. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. 1997; 138(3): 863-70.
31. Barton M, Filardo EJ, Lolait SJ, Thomas P, Maggiolini M, Prossnitz ERJTJosb, et al. Twenty years of the G protein-coupled estrogen receptor GPER: Historical and Personal Perspectives. 2018; 176: 4-15.
32. Verde G, Llobet LID, Wright RH, Quilez J, Peiró S, Dily FL, et al. Unliganded progesterone receptor governs estrogen receptor gene expression by regulating DNA methylation in breast cancer Cells. 2018; 10(10): 371.
33. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BSJE. Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell Phenotype. 2003;144(10):4562-74.
34. Stender JD, Kim K, Charn TH, Komm B, Chang KC, Kraus WL, et al. Genome-wide analysis of estrogen receptor α DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. 2010; 30(16): 3943-55.
35. Mal R, Magner A, David J, Datta J, Vallabhaneni M, Kassem M, et al. Estrogen receptor beta (ERβ): a ligand activated tumor suppressor. 2020;10:587386.
36. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, et al. Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells. 1996;15(6): 1292-300.
37. Yu T, Yang G, Hou Y, Tang X, Wu C, Wu X, et al. Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance. 2017;36(15):2131-45.
38. Steelman LS, Chappell WH, Akula SM, Abrams SL, Cocco L, Manzoli L, et al. Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. 2020;78:100758.
39. Christopoulos PF, Msaouel P, Koutsilieris MJMc. The role of the insulin-like growth factor-1 system in breast cancer. 2015;14(1):1-14.
40. Venkitaraman ARJDr. How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility? 2019; 81: 102668.
41. Santen R, Song R, Zhang Z, Kumar R, Jeng M, Masamura S, et al. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. 2003; 10(2): 111-30.
42. Picotto G, Massheimer V, Boland RJM, endocrinology c. Acute stimulation of intestinal cell calcium influx induced by 17β-estradiol via the cAMP messenger system. 1Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet. 2005; 365(9472): 1727-1741.
43. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast canc. 996; 119(2): 129-34.
44. er and 101 986 women without the disease. The Lancet. 2001 Oct 27; 358(9291): 1389-99.
45. Hulka BS. Epidemiology of susceptibility to breast cancer. Progress in Clinical and Biological Research. 1996 Jan 1;395:159-74.
46. Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E. Breast cancer risk factors. Menopause Review/Przegląd Menopauzalny. 2015 Sep 30;14(3):196-202.
47. Wang J, Costantino JP, Tan-Chiu E, Wickerham DL, Paik S, Wolmark N. Lower-category benign breast disease and the risk of invasive breast cancer. Journal of the National Cancer Institute. 2004 Apr 21;96(8):616-20.
48. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ. Benign breast disease and the risk of breast cancer. New England Journal of Medicine. 2005 Jul 21;353(3):229-37.
49. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. New England Journal of Medicine. 1985 Jan 17;312(3):146-51.
50. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, Schuyler PA, Plummer WD. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993 Feb 15;71(4):1258-65.
51. Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003; 237(4): 474-482.
52. Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM, Harvie MN. Risk determination and prevention of breast cancer. Breast Cancer Research. 2014 Oct; 16(5): 1-9.
53. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, Hirunpat S, Woodtichartpreecha P, Boonlikit S, Teerawattananon Y, Thakkinstian A. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pacific Journal of Public Health. 2013 Sep; 25(5): 368-87.
54. Ozsoy A, Barça N, Dolek BA, Aktaş H, Elverici E, Araz L, Ozkaraoğlu O. The relationship between breast cancer and risk factors: a single-center study. European Journal of Breast Health. 2017 Jul;13(3):145.
55. McTiernan A. Behavioral risk factors in breast cancer: can risk be modified?. The Oncologist. 2003 Aug 1;8(4):326-34.
56. Vogel VG. Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer. Menopause. 2008 Jul 1;15(4):782-9.
57. Byrne C, Webb PM, Jacobs TW, Peiro G, Schnitt SJ, Connolly JL, Willett WC, Colditz GA. Alcohol consumption and incidence of benign breast disease. Cancer Epidemiology Biomarkers & Prevention. 2002 Nov 1;11(11):1369-74.
58. Patterson RE, Cadmus LA, Emond JA, Pierce JP. Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature. Maturitas. 2010 May 1;66(1):5-15.
59. Rock CL, Demark-Wahnefried W. Can lifestyle modification increase survival in women diagnosed with breast cancer?. The Journal of Nutrition. 2002 Nov 1;132(11):3504S-9S.
60. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiology Biomarkers & Prevention. 2007 Mar 1;16(3):439-43.
61. Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2015 Aug 1;1856(1):73-85.
62. Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How many etiological subtypes of breast cancer: two, three, four, or more?. Journal of the National Cancer Institute. 2014 Aug 1;106(8):dju165.
63. Colditz GA, Kaphingst KA, Hankinson SE, Rosner B. Family history and risk of breast cancer: nurses’ health study. Breast Cancer Research and Treatment. 2012 Jun;133:1097-104.
64. Polyak K. Breast cancer: origins and evolution. The Journal of Clinical Investigation. 2007 Nov 1;117(11):3155-63.
65. Allison KH. Molecular pathology of breast cancer: what a pathologist needs to know. American Journal of Clinical Pathology. 2012 Dec 1;138(6):770-80.